Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2003 2
2005 2
2007 2
2009 1
2013 2
2016 2
2017 2
2018 5
2019 3
2020 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
A Systematic Review of the Randomized Controlled Trials of Gemcabene and Its Therapeutic Uses.
Besekar SM, Jogdand SD, Naqvi WM. Besekar SM, et al. Cureus. 2023 Mar 28;15(3):e36811. doi: 10.7759/cureus.36811. eCollection 2023 Mar. Cureus. 2023. PMID: 37123792 Free PMC article. Review.
Furthermore, gemcabenes were discovered in 1995 and are now in phase II and III clinical trials. Gemcabene acts by inhibiting incorporation of 14C-acetate into hepatocytes and stops the mechanism of fatty acids and cholesterol synthesis. ...The study concluded that gemc …
Furthermore, gemcabenes were discovered in 1995 and are now in phase II and III clinical trials. Gemcabene acts by inhibiting incorpo …
Model-based development of gemcabene, a new lipid-altering agent.
Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D. Mandema JW, et al. AAPS J. 2005 Oct 7;7(3):E513-22. doi: 10.1208/aapsj070352. AAPS J. 2005. PMID: 16353929 Free PMC article. Review.
The purpose of this study was to evaluate the value of model-based, quantitative decision making during the development of gemcabene, a novel lipid-altering agent. The decisions were driven by a model of the likely clinical profile of gemcabene in comparison with it …
The purpose of this study was to evaluate the value of model-based, quantitative decision making during the development of gemcabene, …
Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM model of NASH.
Oniciu DC, Hashiguchi T, Shibazaki Y, Bisgaier CL. Oniciu DC, et al. PLoS One. 2018 May 30;13(5):e0194568. doi: 10.1371/journal.pone.0194568. eCollection 2018. PLoS One. 2018. PMID: 29847555 Free PMC article.
METHODS: Gemcabene was evaluated in the STAM murine model of NASH. Gemcabene intervention in mice made diabetic with streptozotocin and fed a high fat high-caloric diet was assessed for changes in plasma, and hepatic histological and mRNA markers of lipid metabolism …
METHODS: Gemcabene was evaluated in the STAM murine model of NASH. Gemcabene intervention in mice made diabetic with streptozo …
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
Gaudet D, Durst R, Lepor N, Bakker-Arkema R, Bisgaier C, Masson L, Golden L, Kastelein JJ, Hegele RA, Stein E. Gaudet D, et al. Am J Cardiol. 2019 Dec 15;124(12):1876-1880. doi: 10.1016/j.amjcard.2019.09.010. Epub 2019 Sep 26. Am J Cardiol. 2019. PMID: 31685212 Clinical Trial.
The present study (COBALT-1) assessed efficacy, tolerability, and safety of gemcabene as an adjunctive therapy to current lipid-lowering treatment for familial hypercholesterolemia patients. ...Patients received 300 mg gemcabene for the first 4 weeks, 600 mg for the …
The present study (COBALT-1) assessed efficacy, tolerability, and safety of gemcabene as an adjunctive therapy to current lipid-lower …
Lipid-Lowering Agents.
Hegele RA, Tsimikas S. Hegele RA, et al. Circ Res. 2019 Feb;124(3):386-404. doi: 10.1161/CIRCRESAHA.118.313171. Circ Res. 2019. PMID: 30702996
Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, and gemcabene primarily target LDL cholesterol. Alipogene tiparvovec, pradigastat, and volanesorsen primarily target elevated triglycerides, whereas evinacumab and IONIS-ANGPTL3-L(Rx) target both LDL chole …
Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, and gemcabene primarily target LDL cholesterol. Alipogene tiparvo …
Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-delta-mediated transcriptional mechanism.
Srivastava RAK, Cornicelli JA, Markham B, Bisgaier CL. Srivastava RAK, et al. Mol Cell Biochem. 2018 Dec;449(1-2):167-183. doi: 10.1007/s11010-018-3353-5. Epub 2018 Apr 11. Mol Cell Biochem. 2018. PMID: 29644527 Free PMC article.
In human hepatoma cells, gemcabene inhibited IL-6 plus IL-1beta-induced CRP production in a concentration-dependent manner, reaching 70% inhibition at 2 mM. ...Luciferase activity was reduced by 50% by gemcabene, suggesting transcriptional down-regulation of CRP. Si …
In human hepatoma cells, gemcabene inhibited IL-6 plus IL-1beta-induced CRP production in a concentration-dependent manner, reaching …
Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain.
Srivastava RAK, Cornicelli JA, Markham B, Bisgaier CL. Srivastava RAK, et al. Front Pharmacol. 2018 May 11;9:471. doi: 10.3389/fphar.2018.00471. eCollection 2018. Front Pharmacol. 2018. PMID: 29867478 Free PMC article.
Our clinical studies have demonstrated that gemcabene, a small molecule in late-stage clinical development, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP). ...We also evaluated efficacy of gemcabene in collagen antibody-induced joint swelling …
Our clinical studies have demonstrated that gemcabene, a small molecule in late-stage clinical development, lowers pro-inflammatory a …
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients.
Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Stein E, et al. J Clin Lipidol. 2016 Sep-Oct;10(5):1212-22. doi: 10.1016/j.jacl.2016.08.002. Epub 2016 Aug 10. J Clin Lipidol. 2016. PMID: 27678439 Free article. Clinical Trial.

OBJECTIVE: To evaluate the LDL-C lowering and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. ...The median percent change in CRP was -26.1% (P = .196) and -53.9% (P < .001) for gemcabene 300 mg and 900 mg, respectively, v

…
OBJECTIVE: To evaluate the LDL-C lowering and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients …
New oral agents for treating dyslipidemia.
Gryn SE, Hegele RA. Gryn SE, et al. Curr Opin Lipidol. 2016 Dec;27(6):579-584. doi: 10.1097/MOL.0000000000000354. Curr Opin Lipidol. 2016. PMID: 27676196 Review.
RECENT FINDINGS: Recent data support statins for intermediate risk primary prevention, and ezetimibe for high-risk secondary prevention. Novel agents in development include bempedoic acid and gemcabene, and work continues on one remaining cholesteryl ester transfer protein …
RECENT FINDINGS: Recent data support statins for intermediate risk primary prevention, and ezetimibe for high-risk secondary prevention. Nov …
Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
Bisgaier CL, Oniciu DC, Srivastava RAK. Bisgaier CL, et al. J Cardiovasc Pharmacol. 2018 Jul;72(1):3-10. doi: 10.1097/FJC.0000000000000580. J Cardiovasc Pharmacol. 2018. PMID: 29621036 Free PMC article.
In the current study, the gemcabene agonist activity against PPAR subtypes of human, rat, and mouse were compared with known lipid lowering PPAR activators. ...For PPAR-gamma, gemcabene showed no agonist activity against all 3 species at 100 muM and marginal activit …
In the current study, the gemcabene agonist activity against PPAR subtypes of human, rat, and mouse were compared with known lipid lo …
28 results